Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial
Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS).
Obexelimab met its primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009.
The Company is committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases.
Author's summary: Zenas BioPharma reports positive results.
More News
- US Secretary of War pays official visit to Vietnam
- Taking initiative in the context of digital education
- EXCLUSIVE: Tory Lanez Must Sit For Another Megan Thee Stallion Deposition
- Solicitor judge reappointed as senior judicial commissioner
- EXCLUSIVE: Rich The Kid Faces Massive Judgment After Secret Affair & Broken Deal
- Why we need to get smarter about adaptation